PACIRA BIOSCIENCES, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
PACIRA BIOSCIENCES, INC. (PCRX) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $24.70 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-04
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $24.70M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $43.00M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $14.30M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $28.60M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $24.70M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $43.00M 10-Q · filed 2026-04-30 |
| 2025-09-30 | $14.30M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $28.60M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $43.00M 10-Q · filed 2025-05-08 |
| 2024-09-30 | $14.30M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $28.60M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $43.00M 10-Q · filed 2024-05-07 |
| 2023-09-30 | $14.30M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $28.60M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $43.00M 10-Q · filed 2023-05-03 |
| 2022-09-30 | $14.30M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $28.60M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $43.00M 10-Q · filed 2022-05-04 |
| 2021-09-30 | $2.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $3.90M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $5.90M 10-Q · filed 2021-05-04 |
| 2020-09-30 | $2.00M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $3.90M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.90M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $2.00M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $3.90M 10-Q · filed 2019-08-08 |
| 2013-09-30 | $513.00K 10-Q · filed 2013-10-31 |
| 2013-06-30 | $1.03M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $1.54M 10-Q · filed 2013-05-08 |
| 2012-09-30 | $514.00K 10-Q · filed 2012-11-01 |
| 2012-06-30 | $1.03M 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |